Promise publishes articles about prescription peptides, GLP-1 medications and the rules around them. These editorial standards are what every one of those articles is held to, written down so you can hold us to them too. If a piece on this site falls short of what is on this page, tell us and we will fix it.
Editorial standards
How we research, write and correct what we publish
Last updated: September 17, 2026
In brief.
Who writes the articles
Articles are written and edited by the Promise editorial team, working to the standards on this page. Every piece goes through the same steps before it is published: the sources are opened and checked, the claims are read against the rules below, and the article is dated. Questions about a specific article can go to support@mypromise.com.
Sources you can open
Every article links to the primary source behind its claims: the published study on PubMed or the journal's own site, the FDA record, the drug label, the text of the rule. We link to the source itself rather than to someone else's summary of it, and we open each one before an article goes live to confirm it says what we say it says.
When the evidence is thin, we say that. Much of the peptide literature is animal or early-stage human research, and an article that cites a rat study calls it a rat study.
What our articles will not claim
- No promised results. We describe what a treatment has been studied for and how it is thought to work. We do not say it cures, guarantees or is proven to do anything.
- No blurred regulatory status. Compounded medications are not FDA-approved, and every treatment page and article about one says so plainly. Where a brand-name product built on the same molecule has been approved, we explain that the approval does not extend to the compounded formulation.
- No medical advice. An article can explain how a medication works. Whether it is right for you is decided by a licensed provider who has read your health history, and sometimes that answer is no.
Dates on everything
Every article shows the date it was published. News pieces state what was known as of the day they were written, because a regulatory story can change in a week.
Articles are re-reviewed at least once a year, and sooner when something material changes: a new approval, a new label warning, a new rule.
Corrections
When we get something wrong, we correct the article itself rather than publishing a quiet follow-up somewhere else. One rule governs every safety edit: a safety statement only ever becomes more precise, never more permissive.
Found an error? Email support@mypromise.com with the page address and what you believe is wrong. Include a source if you have one.
Where the business sits
Promise offers prescription treatments, and our articles link to the treatment pages they discuss. What an article says about evidence, side effects and regulatory status does not change because we offer the treatment. Several of our most-read pieces are about who should not take a medication, and why a provider might decline to prescribe it.
Articles are never a substitute for the visit. Every treatment request is reviewed by a licensed provider, and not everyone qualifies.